Global Bipolar Disorder Therapeutics Market Research Report 2022 - Market Size, Current Insights and Development Trends
SKU ID :Maia-21752842 | Published Date: 23-Sep-2022 | No. of pages: 96Description
Bipolar disorder, also known as manic depression, leads to extreme changes in mood, energy and activity levels. Elevated mood swings are known as mania or mild mania, which vary according to the severity and presence of the mental illness.
The Bipolar Disorder Therapeutics market has witnessed a growth from USD XX million to USD XX million from 2017 to 2022. With a CAGR of X.X%, this market is estimated to reach USD XX million in 2029.
The report focuses on the Bipolar Disorder Therapeutics market size, segment size (mainly covering product type, application, and geography), competitor landscape, recent status, and development trends. Furthermore, the report provides strategies for companies to overcome threats posed by COVID-19.
Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market. Moreover, customer preference analysis, market dynamics (drivers, restraints, opportunities), new product release, impact of COVID-19, regional conflicts and carbon neutrality provide crucial information for us to take a deep dive into the Bipolar Disorder Therapeutics market.
Major Players in the Bipolar Disorder Therapeutics market are:
Intra-Cellular Therapies
Reviva Pharmaceuticals
Omeros Corporation
Delpor
D Pharm
H. Lundbeck
AbbVie
Astellas
Gedeon Richter
Janssen Pharmaceuticals
GSK
Noven Pharmaceuticals
Eli Lilly
Abital Pharma
Convergence Pharmaceuticals
Pfizer
Allergan
BMS
Otsuka
AstraZeneca
Sunovion Pharmaceutical.
Novartis
SK Biopharmaceuticals
PNBDevCo
On the basis of types, the Bipolar Disorder Therapeutics market is primarily split into:
Antipsychotics
Anticonvulsants
Traditional mood stabilizers
Others
On the basis of applications, the market covers:
Hospital
Clinic
United States
Europe
China
Japan
India
Southeast Asia
Latin America
Middle East and Africa
Others
2021
The Bipolar Disorder Therapeutics market has witnessed a growth from USD XX million to USD XX million from 2017 to 2022. With a CAGR of X.X%, this market is estimated to reach USD XX million in 2029.
The report focuses on the Bipolar Disorder Therapeutics market size, segment size (mainly covering product type, application, and geography), competitor landscape, recent status, and development trends. Furthermore, the report provides strategies for companies to overcome threats posed by COVID-19.
Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market. Moreover, customer preference analysis, market dynamics (drivers, restraints, opportunities), new product release, impact of COVID-19, regional conflicts and carbon neutrality provide crucial information for us to take a deep dive into the Bipolar Disorder Therapeutics market.
Major Players in the Bipolar Disorder Therapeutics market are:
Intra-Cellular Therapies
Reviva Pharmaceuticals
Omeros Corporation
Delpor
D Pharm
H. Lundbeck
AbbVie
Astellas
Gedeon Richter
Janssen Pharmaceuticals
GSK
Noven Pharmaceuticals
Eli Lilly
Abital Pharma
Convergence Pharmaceuticals
Pfizer
Allergan
BMS
Otsuka
AstraZeneca
Sunovion Pharmaceutical.
Novartis
SK Biopharmaceuticals
PNBDevCo
On the basis of types, the Bipolar Disorder Therapeutics market is primarily split into:
Antipsychotics
Anticonvulsants
Traditional mood stabilizers
Others
On the basis of applications, the market covers:
Hospital
Clinic
Major Region
s or countries covered in this report:United States
Europe
China
Japan
India
Southeast Asia
Latin America
Middle East and Africa
Others
Years considered for this report:
Historical Years:
2017-2021Base Year:
2021Estimated Year:
2022Forecast Period:
2022-2029TOC
Tables & Figures
Companies
- PRICE
-
$3450$6900$4600Buy Now